{"contentid": 488576, "importid": NaN, "name": "China NMPA conditional nod for pamiparib in ovarian cancer", "introduction": "The PARP inhibitor pamiparib has received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of patients with germline BRC (gBRCA) mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy.", "content": "<p>The PARP inhibitor pamiparib has received conditional approval from the China National Medical Products Administration (NMPA) for the treatment of patients with germline BRC (gBRCA) mutation-associated recurrent advanced ovarian, fallopian tube, or primary peritoneal cancer who have been treated with two or more lines of chemotherapy, said the drug&rsquo;s developer, Chinese biotech BeiGene (Nasdaq: BGNE).</p>\n<p>The new drug application was previously granted priority review by the Center for Drug Evaluation (CDE) in July 2020. BeiGene says it is preparing to launch pamiparib this month.</p>\n<p>In August 2018, the NMPA approved AstraZeneca's (LSE: AZN) Lynparza (olaparib) for the maintenance treatment of recurrent platinum-sensitive ovarian cancer, making it the first targeted therapy approved for the indication in China.</p>\n<p>&ldquo;Today&rsquo;s NMPA approval makes pamiparib the third BeiGene internally discovered and developed medicine to receive marketing authorization, an incredible company milestone validating our scientific innovations,&rdquo; commented Xiaobin Wu, president, chief operating officer, and general manager of China at BeiGene. &ldquo;With a broad commercial portfolio of seven medicines covering 15 indications across hematological malignancies and solid tumors in China, our science-based commercial team is well-positioned to serve patients in need. BeiGene will continue working to advance our broad, diverse pipeline and executing on our mission of expanding access to and improving affordability of impactful treatments for patients worldwide,&rdquo; he added.</p>\n<h2>Clinical backing</h2>\n<p>The NMPA conditional approval of pamiparib for the treatment of patients with advanced ovarian, fallopian tube, or primary peritoneal cancer is based on clinical results from a pivotal Phase II portion of the Phase I/II trial (NCT03333915). A total of 113 patients in China with high-grade, non-mucinous, epithelial ovarian cancer (including fallopian or primary peritoneal cancer), harboring gBRCA mutations, following at least two prior lines of standard chemotherapy, were enrolled in the pivotal Phase 2 portion of the trial, including 90 patients with advanced platinum-sensitive ovarian cancer (PSOC), and 23 patients with advanced platinum-resistant ovarian cancer (PROC).</p>\n<p>Full approval for this indication is contingent on results from ongoing corroborative trials confirming the clinical benefit of pamiparib in this population.</p>", "date": "2021-05-08 15:28:00", "meta_title": "China NMPA conditional nod for pamiparib in ovarian cancer", "meta_keywords": "BeiGene, China, NMPA, Approval, Conditional Pamiparib, Cancer, Ovaria, Fallopian tube", "meta_description": "China NMPA conditional nod for pamiparib in ovarian cancer", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-08 15:21:54", "updated": "2021-05-08 15:29:18", "access": NaN, "url": "https://www.thepharmaletter.com/article/china-nmpa-conditional-nod-for-pamiparib-in-ovarian-cancer", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "china_regulator_cnmpa_big.jpg", "image2id": "china_regulator_cnmpa_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": "Ovarian cancer", "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Asia Pacific, Focus On, Regulation", "geography_tag": "China", "company_tag": "BeiGene", "drug_tag": "pamiparib", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": "China National Medical Products Association", "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-08 15:28:00"}